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Abstract 
PCD is a condition in which abnormal cilia structure or function leads to reduced mucociliary 
clearance and obstructive lung disease.  29 patients had LCI measured in 2009 and we 
attempted to perform a 5 year follow up.  Only 12 patients could be re-recruited, but in this 
small group LCI was stable over the 5 years, which confirms previous data showing 
spirometry is also stable in these patients over the medium term.  The two patients with the 
highest LCI in 2009 had since died, despite one having relatively preserved spirometry at the 
time.  This data may be used to inform sample size calculations of future studies. 
 
 
Introduction 
PCD is a rare, inherited condition where defects in the structure or function of the cilia cause 
reduced mucociliary clearance leading to repeated infection and inflammation and 
subsequently bronchiectasis.  PCD is a heterogeneous condition caused by mutations in 
many different genes [1, 2]. 
 
PCD airway disease and its treatment show similarities with cystic fibrosis (CF).  However in 
PCD the rate of decline in spirometry is less than in CF, if it occurs at all [3, 4]. 
 
Spirometry is abnormal in CF and PCD in cross sectional studies[5–7], but lung clearance 
index (LCI), derived from the multiple breath washout (MBW) test, is more sensitive, and is 
the first lung function test to become abnormal  in longitudinal studies in CF[8, 9].  
Longitudinal changes in LCI in PCD have not been reported. Here, we report on a small 
cohort of PCD patients who had MBW and spirometry in 2009-10 and five years later to 
investigate which measure changed more over time. We hypothesised that, as with CF, LCI 
would decline more rapidly than spirometry. 
 
Methods 
29 PCD patients were recruited from adult and paediatric PCD clinics at the Royal Brompton, 
and had a confirmed diagnosis of PCD by either genotype or ultrastructural abnormality on 
electron microscopy, in accordance with ERS diagnostic guidelines [10].  13/29 patients had 
situs abnormalities.  Patients had their first MBW in 2009-10.  12 had repeat measures five 
years later in 2014-15. Seven patients declined to take part, two had died and eight were 
lost to follow up from our centre.  Median age at first visit was 14 years (range 3 to 53), 9 
were males, median LCI at first visit was 11.37 (range 7.24 to 14.98) and median initial one 
second expired volume (FEV1) z score was -2.93 (range -0.01 to -6.08). MBW and spirometry 
were performed using identical equipment and methods at both visits. MBW was carried out 
using a photoacoustic gas analyser (Innocor, Innovision, Denmark) in an open circuit 
washout using sulphur hexafluoride tracer gas, as described previously[6, 11].  LCI was 
calculated as the mean of at least 2 acceptable tests.  All patients completed at least 2 
acceptable manoeuvres.  
 
All patients performed spirometry acceptable within ATS/ERS guidelines, except the 
youngest patient in the cohort (age 3 at first measurement), who is only included in the LCI 
analysis. Measurements were compared using the Wilcoxon matched pairs test.  
 
Results 
There was no significant difference in age, ethnicity or lung function between those re-
recruited and those lost to follow up. There was no significant difference between the 
results in 2010-2015 (Figure) for LCI or FEV1 z score.  There was a mean difference in LCI -0.3 
units (4%, p=NS); there was a mean difference in FEV1 difference of 0.4 z scores (16%, p=NS).   
There was no correlation between LCI and FEV1 z score at either visit, or change in LCI and 
FEV1 z score.  One patient had a 63% improvement in LCI and a 21% improvement in FEV1, 
following treatment for concurrent asthma.  One patient had a 34% worsening of LCI, 
following a clinical decline and the development of bronchiectasis; this was the youngest 
patient who could not perform acceptable spirometry at first visit.  If these patients are 
removed from both analyses (LCI and FEV1) this does not alter the conclusions and there 
remains no significant change.    
 
The 2 patients who had died had the highest LCIs, including those that were lost to follow up 
or who declined to take part; one deceased patient also had poor spirometry (LCI 17.63 FEV1 
-5.3) but spirometry was relatively preserved in the other (LCI 18.69, FEV1 -2.3) at the first 
visit. 
 
 
Discussion 
In this small cohort, there was no significant change in LCI or FEV1 over 5 years, suggesting 
that LCI may not offer any advantage over spirometry.  Highly anecdotally, a very high LCI 
may be a bad prognostic sign, and LCI may be more treatment-responsive than spirometry, 
although both need to be confirmed by a prospective study. 
 
The chief weakness of this study is small sample size.  Although 29 patients had tests in 
2009-10 fewer than 50% were re-recruited.  Also, as most of the patients had shared care 
arrangements with local hospitals, full treatment and medication history over the 5 year 
period is not available. Our findings should be confirmed in a larger prospective cohort 
study.    
 
 
Our stable spirometry confirm previous studies suggesting in tertiary centres[3].  Contrary to 
our hypothesis, LCI did not change either, suggesting that using LCI as an end-point in long-
term longitudinal studies may not offer any advantage over spirometry in PCD. However, the 
respective roles of spirometry and MBW in short-term intervention trials of treatment 
merits further study; certainly in CF, using LCI as an end-point allows sample size to be 
reduced[12].  These results may better allow sample sizes for larger studies to be generated. 
 
Figure - 5 year stability of lung function measurements in PCD.  There is no significant 
difference in LCI or FEV1 z score between the years. Patients marked “x” are have only one 
set of measurements.  Patients marked  and  have died. Dotted lines show the limits of 
normality. 
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